NASDAQ · RDHL
Healthcare · Drug Manufacturers - Specialty & Generic
$0.47
Down-$0.01 (-2.07%)
Updated Oct 8, 2026, 1:15 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RDHL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
RDHL closed at $0.47 after 21 trading sessions, down 31.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $0.4712 | $0.4964 | $0.4712 | $0.474 | 36.15K |
| Oct 6, 2026 | $0.495 | $0.4998 | $0.4751 | $0.484 | 58.89K |
| Oct 5, 2026 | $0.50 | $0.508 | $0.49 | $0.4928 | 91.87K |
| Oct 2, 2026 | $0.515 | $0.515 | $0.4881 | $0.50 | 131.23K |
| Oct 1, 2026 | $0.465 | $0.492 | $0.4647 | $0.48 | 564.38K |
| Sep 30, 2026 | $0.48 | $0.5013 | $0.4793 | $0.48 | 220.76K |
| Sep 29, 2026 | $0.4908 | $0.4961 | $0.4752 | $0.4813 | 92.59K |
| Sep 28, 2026 | $0.50 | $0.5185 | $0.49 | $0.5055 | 91.58K |
| Sep 25, 2026 | $0.5252 | $0.5252 | $0.50 | $0.50 | 102.86K |
| Sep 24, 2026 | $0.5432 | $0.5557 | $0.52 | $0.5204 | 90.7K |
| Sep 23, 2026 | $0.53 | $0.55 | $0.524 | $0.5431 | 80.29K |
| Sep 22, 2026 | $0.545 | $0.5682 | $0.5199 | $0.541 | 204.32K |
| Sep 21, 2026 | $0.56 | $0.5679 | $0.5385 | $0.5499 | 78.28K |
| Sep 18, 2026 | $0.5796 | $0.59 | $0.56 | $0.5683 | 84.99K |
| Sep 17, 2026 | $0.57 | $0.5999 | $0.57 | $0.5928 | 230.83K |
| Sep 16, 2026 | $0.57 | $0.5801 | $0.5405 | $0.55 | 222.42K |
| Sep 15, 2026 | $0.60 | $0.60 | $0.56 | $0.5751 | 252.92K |
| Sep 14, 2026 | $0.62 | $0.62 | $0.59 | $0.6139 | 208.61K |
| Sep 11, 2026 | $0.655 | $0.6799 | $0.62 | $0.6449 | 265.85K |
| Sep 10, 2026 | $0.70 | $0.70 | $0.6533 | $0.6533 | 153.03K |
| Sep 9, 2026 | $0.65 | $0.7097 | $0.65 | $0.6964 | 231.76K |
The latest Smart Investors Daily articles mentioning RDHL.
Company
Market Activity
Research & News
RDHL research
Company profile and research snapshot.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2021 | HC Wainwright & Co. | Buy | — |
| Aug 31, 2021 | Cantor Fitzgerald | Overweight | — |
| May 28, 2021 | WBB Securities | Buy | — |
| May 18, 2021 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2020 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 30, 2026
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported operational highlights and financial results for the six months ended June 30, 2026.
Benzinga · Sep 30, 2026
Redhill Biopharma (NASDAQ:RDHL) reported H1 2026 EPS $0.00 And Revenue $0.00.
Yahoo · Sep 10, 2026
RedHill Biopharma Ltd. (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq from Ferring Pharmaceuticals. The agreement has an initial 13-year term and automatically renews for successive two-year periods unless either party elects not to renew. RedHill Biopharma Ltd. (NASDAQ:RDHL) paid $12 million upfront, funded from the $18 million […]
ChartMill · Sep 1, 2026
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDHL.
No results
No recent SID articles mention RDHL.
